

UC San Diego

UC San Diego Previously Published Works

Title

Explication of CB1 receptor contributions to the hypothermic effects of  $\Delta^9$ -tetrahydrocannabinol (THC) when delivered by vapor inhalation or parenteral injection in rats

Permalink

<https://escholarship.org/uc/item/59n4t4hs>

Authors

Nguyen, Jacques D

Creehan, KM

Grant, Yanabel

et al.

Publication Date

2020-09-01

DOI

10.1016/j.drugalcdep.2020.108166

Peer reviewed



Published in final edited form as:

*Drug Alcohol Depend.* 2020 September 01; 214: 108166. doi:10.1016/j.drugalcdep.2020.108166.

## Explication of CB<sub>1</sub> receptor contributions to the hypothermic effects of <sup>9</sup>-tetrahydrocannabinol (THC) when delivered by vapor inhalation or parenteral injection in rats

Jacques D. Nguyen<sup>1,2</sup>, K. M. Creehan<sup>1,2</sup>, Yanabel Grant<sup>1,2</sup>, Sophia A. Vandewater<sup>1</sup>, Tony M. Kerr<sup>1</sup>, Michael A. Taffe<sup>1,2</sup>

<sup>1</sup>Department of Neuroscience, The Scripps Research Institute, La Jolla, CA USA

<sup>2</sup>Department of Psychiatry, University of California San Diego, La Jolla, CA USA

### Abstract

The use of <sup>9</sup>-tetrahydrocannabinol (THC) by inhalation using e-cigarette technology grows increasingly popular for medical and recreational purposes. This has led to development of e-cigarette based techniques to study the delivery of THC by inhalation in laboratory rodents. Inhaled THC reliably produces hypothermic and antinociceptive effects in rats, similar to effects of parenteral injection of THC. This study was conducted to determine the extent to which the hypothermic response depends on interactions with the CB<sub>1</sub> receptor, using pharmacological antagonist (SR141716, AM-251) approaches. Groups of rats were implanted with radiotelemetry devices capable of reporting activity and body temperature, which were assessed after THC inhalation or injection. SR141716 (4 mg/kg, i.p.) blocked or attenuated antinociceptive effects of acute THC inhalation in male and female rats. SR141716 was unable to block the initial hypothermia caused by THC inhalation, but temperature was restored to normal more quickly. Alterations in antagonist pre-treatment time, dose and the use of a rat strain with less sensitivity to THC-induced hypothermia did not change this pattern. Pre-treatment with SR141716 (4 mg/kg, i.p.) blocked hypothermia induced by i.v. THC and reversed hypothermia when administered 45 or 90 minutes after THC (i.p.). SR141716 and AM-251 (4 mg/kg, i.p.) sped recovery from, but did not block, hypothermia caused by vapor THC in female rats made tolerant by prior repeated THC vapor inhalation. The CB<sub>2</sub> antagonist AM-630, had no effect. These results suggest that hypothermia consequent to THC inhalation is induced by other mechanisms in addition to CB<sub>1</sub> receptor activation.

Correspondence and requests for materials should be addressed to Dr. Michael A. Taffe, Department of Psychiatry; 9500 Gilman Dr. MC 0714; University of California San Diego, La Jolla, CA 92093; USA; Phone: +1.858.246.5638; Fax: +1.858.784.7405; mtaffe@ucsd.edu.

Author Contributions:

MAT and JDN designed the studies, with refinements contributed by KMC, YG, TMK and SAV. JDN, KMC, YG, TMK and SAV performed the research and conducted initial data analysis. MAT conducted statistical analysis of data, created figures and wrote the major drafts of the paper, assisted by JDN. All authors approved of the submitted version of the manuscript.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Competing Interest:** SAV has consulted for LJARI.

## Keywords

cannabis; marijuana; hypothermia; nociception; vape; e-cigarette

---

## 1. Introduction

A substantial and sustained decrease in body temperature, and a reduction in sensitivity to a noxious stimulus (antinociception), are two major indicators of cannabinoid activity in laboratory rodents (Abel, 1973; Borgen et al., 1973; Lichtman and Martin, 1990; Taylor and Fennesy, 1977; Vidal et al., 1984; Wiley et al., 2014). The exogenous cannabinoid compound  $\Delta^9$ -tetrahydrocannabinol (THC) also decreases the body temperature of monkeys (McMahon et al., 2005; Taffe, 2012), dogs (Hardman et al., 1971), cats (Schmelting and Hosko, 1980) and other species, as summarized (Clark and Clark, 1981).

Effects of THC on temperature appear to mostly be mediated via the CB<sub>1</sub> receptor since the CB<sub>1</sub> antagonist/inverse agonists SR141716 (Rimonabant) and AM-251 have been shown to block effects of cannabinoid agonists such as THC when delivered by parenteral injection (Grim et al., 2017; Taffe et al., 2015) and deletion of the CB<sub>1</sub> receptor in mice prevents hypothermic responses to THC (Wang et al., 2020; Zimmer et al., 1999). In addition, SR141716, and another CB<sub>1</sub> antagonist AM-251, prevented hypothermic and antinociceptive effects of THC, i.p., but failed to reverse hypolocomotor effects, in male C57BL/6J mice (McMahon and Koek, 2007). SR141716 only partially reversed rectal temperature hypothermia observed 2 h after injection in chair restrained rhesus monkeys (McMahon et al., 2005), but fully prevented the hypothermia in unrestrained monkeys for the first 3 hours after intramuscular injection in another study (Taffe, 2012); this difference may be due to the relative duration of action of SR141716 versus THC since the former paper did not report temperature prior to 2 h after injection. Additionally, SR141716 failed to reverse the effects of THC on operant responding in monkeys (McMahon et al., 2005).

The majority of human THC consumption occurs via the inhalation route from the smoking of combusted plant material or, more recently, inhalation of vapor created without combustion (Hazekamp et al., 2006; Morean et al., 2015; Morean et al., 2017; Perrine et al., 2019; Zuurman et al., 2008). Despite this, pre-clinical animal models of non-combusted cannabinoid inhalation have been relatively rare (Lichtman et al., 2000; Lichtman et al., 2001; Wilson et al., 2002) until recently (Javadi-Paydar et al., 2018; Lefever et al., 2017; Nguyen et al., 2016). Interestingly this approach has also shown evidence for reward-seeking behavior in rats (Freels et al., 2020).

Antagonist effects of SR141716 have been demonstrated following the *inhalation* of THC (or cannabis smoke) but efficacy may be more variable. SR141716 blocked hypolocomotive effects of marijuana smoke inhalation in rats (Bruijnzeel et al., 2016) and fully blocked antinociception caused by aerosolized THC, but only partially blocked the antinociceptive effects of cannabis smoke inhalation, in male ICR mice (Lichtman et al., 2000; Lichtman et al., 2001). Importantly, SR141716 fully reversed the antinociceptive, hypothermic and cataleptic effects of THC when administered *intravenously* in the same behavioral model (Lichtman et al., 2001). SR141716 blocked thermoregulatory, antinociceptive and locomotor

effects of inhaled THC in Swiss Webster mice (Marshall et al., 2014) and our original paper showed that SR141716 blocked the antinociceptive effects of inhaled THC (Nguyen et al., 2016), however, no evidence regarding the effect of SR141716 on THC inhalation-induced hypothermia was included in the latter study. The fact that SR141716 does not always fully block effects of THC may depend on outcome measure, species, THC dose or other as yet unexplained factors such as the route of administration. As humans continue to ingest THC via e-cigarette technology it has become increasingly important to develop translational pre-clinical models that are capable of evaluating the consequences of this route of administration. One important part of this development is determining similarities and differences with prior pre-clinical work with other routes of exposure.

The present study set out to determine if SR141716 is capable of blocking the hypothermia induced by the inhalation of THC vapor produced by e-cigarette devices. Our very first observation, conducted in the group of animals used for our initial report (Nguyen et al., 2016), but not reported therein, found that SR141716 did not attenuate the initial drop in body temperature observed after THC inhalation. Body temperature did, however, appear to return to the normal range more quickly. More recently we have reported that SR141716 fails to block the hypothermia induced by the inhalation of THC in both Wistar and Sprague-Dawley male rats, despite preventing hypothermia caused by i.p. injection of THC in each strain (Taffe et al., 2020). This study further explored these observations first by altering the treatment time for the SR141716 antagonist relative to THC exposure by inhalation or i.p. injection. We next administered a higher dose of SR141716 in a group of Wistar rats, which are less sensitive to the temperature disrupting effects of THC compared with Sprague-Dawley rats (Taffe et al., 2020). We next evaluated the effects of SR141716, another CB1 antagonist (AM-251) and the CB2 antagonist AM-630 in a group of female rats made tolerant to THC hypothermia via a twice-daily repeated THC regimen. Finally, we determined plasma THC concentrations after vapor inhalation and i.p. injection of THC in male and female groups of Wistar and Sprague-Dawley rats to determine if any differences in SR141716 efficacy across routes of administration are due to a substantially different THC dose.

## 2. Methods

### 2.1. Subjects

Male (N=27) and female (N=29) Wistar (Charles River, New York) and male (N=22) and female (N=6) Sprague-Dawley (Harlan, Livermore, CA) rats were housed in humidity- and temperature-controlled ( $23\pm 2$  °C) vivaria on 12:12 hour light:dark cycles. Rats had *ad libitum* access to food and water in their home cages and all experiments were performed in the rats' scotophase. Rats entered the laboratory at 10–11 weeks of age. All procedures were conducted under protocols approved by the Institutional Care and Use Committee of The Scripps Research Institute.

### 2.2. Radiotelemetry

Groups of female Wistar (N=16), male Sprague-Dawley (N=16) and male Wistar (N=21) rats were implanted with sterile radiotelemetry transmitters (Data Sciences International, St

Paul, MN) in the abdominal cavity as previously described (Taffe et al., 2015; Wright et al., 2012). Animals were evaluated in clean standard plastic homecages (thin layer of bedding) in a dark testing room, separate from the vivarium, during the (vivarium) dark cycle. Radiotelemetry transmissions were collected via telemetry receiver plates (Data Sciences International, St Paul, MN; RPC-1 or RMC-1) placed under the cages as described in prior investigations (Aarde et al., 2013; Miller et al., 2013). Test sessions for inhalation studies started with a 15-minute interval to ensure data collection, then a 15-minute interval for baseline temperature and activity values followed by initiation of vapor sessions. The 15-minute baseline was omitted for the studies with intraperitoneal injection of THC due to the delayed onset of hypothermia (Nguyen et al., 2016; Taffe et al., 2015). Drugs or vehicle for the antagonist studies were injected prior to, or after, THC administration as specified in the following experimental descriptions.

## 2.2. Intravenous catheterization

Groups of rats were anesthetized with an isoflurane/oxygen vapor mixture (isoflurane 5% induction, 1–3% maintenance) and prepared with chronic indwelling intravenous catheters as described previously (Aarde, Huang & Taffe, 2017; Miller, Aarde, Moreno, Creehan, Janda & Taffe, 2015; Nguyen, Grant, Creehan, Vandewater & Taffe, 2017). Briefly, the intravenous catheters consisted of a 14.5-cm length of polyurethane based tubing (Micro-Renathane®, Braintree Scientific, Inc, Braintree, MA) fitted to a guide cannula (Plastics One, Roanoke, VA) curved at an angle and encased in dental cement anchored to an ~3 cm circle of durable mesh. Catheter tubing was passed subcutaneously from the animal's back to the right jugular vein. Catheter tubing was inserted into the vein and tied gently with suture thread. A liquid tissue adhesive was used to close the incisions (3M™ Vetbond™ Tissue Adhesive: 1469SB, 3M, St. Paul, MN). A minimum of 4 days was allowed for surgical recovery prior to starting an experiment. For the first three days of the recovery period, an antibiotic (cefazolin, i.v.) and an analgesic (flunixin, s.c.) were administered daily. During testing, intravenous catheters were flushed with ~0.2–0.3 ml heparinized (166.7 USP/ml) saline 2–3 times per week. Animals were excluded if catheter patency failure occurred (and no blood could be drawn) or if the external port had been chewed off by a cage mate.

## 2.3. Materials

<sup>9</sup>-tetrahydrocannabinol (THC) was administered by vapor inhalation with doses described by the concentration in the propylene glycol (PG) vehicle and duration of inhalation as in prior studies (Javadi-Paydar et al., 2018; Nguyen et al., 2016). THC was also administered intraperitoneally in a dose of 10 mg/kg, which produces robust temperature responses (Nguyen et al., 2016; Taffe et al., 2015). SR141716 (Rimonabant; SR), AM-251 or AM-630 were administered intraperitoneally in a dose of 4 mg/kg. For injection, THC, SR, AM-251 or AM-630 were suspended in a vehicle of 95% ethanol, Cremophor EL and saline in a 1:1:8 ratio. The THC was provided by the U.S. National Institute on Drug Abuse; SR141716 was obtained from ApexBio (New Delhi, Delhi, India; Distributor: Fisher Scientific, Pittsburgh, PA, USA); AM-251 and AM-630 were obtained from Tocris Bioscience (Avonmouth, Bristol, UK; Distributor: Fisher Scientific, Pittsburgh, PA, USA).

## 2.4. Inhalation Apparatus

Sealed exposure chambers were modified from the 259 mm × 234 mm × 209 mm Allentown, Inc (Allentown, NJ) rat cage to regulate airflow and the delivery of vaporized drug to rats as has been previously described (Nguyen et al, 2016a; Nguyen et al, 2016b). An e-vape controller (Model SSV-1; La Jolla Alcohol Research, Inc, La Jolla, CA, USA) was triggered to deliver the scheduled series of puffs (410 second puffs, 2 second intervals, every 5 minutes) from Protank 3 Atomizer (Kanger Tech; Shenzhen Kanger Technology Co.,LTD; Fuyong Town, Shenzhen, China) e-cigarette cartridges by MedPC IV software (Med Associates, St. Albans, VT USA). The chamber air was vacuum-controlled by a chamber exhaust valve (i.e., a “pull” system) to flow room ambient air through an intake valve at ~1 L per minute. This also functioned to ensure that vapor entered the chamber on each device triggering event. The vapor stream was integrated with the ambient air stream once triggered.

## 2.5. Nociception Assay

Tail-withdrawal antinociception was assessed using a water bath (Bransonic® CPXH Ultrasonic Baths, Danbury, CT) maintained at 52°C as previously described (Javadi-Paydar et al., 2018; Nguyen et al., 2016). The latency to withdraw the tail was measured using a stopwatch, and a cutoff of 15 seconds was used to avoid any possible tissue damage (Wakley and Craft, 2011; Wakley et al, 2014). Tail-withdrawal was assessed 35, 60 and 120 minutes after the initiation of inhalation. The investigator performing the assay was blinded to the treatment condition for a given subject.

## 2.6. Plasma THC analysis

Blood samples were collected (~300–500 µl) via jugular needle insertion following anesthesia with an isoflurane/oxygen vapor mixture (isoflurane 5% induction) or via implanted catheter for groups prepared for i.v. sampling. Plasma THC content was quantified using fast liquid chromatography/mass spectrometry (LC/MS) adapted from (Irimia, Polis, Stouffer, & Parsons, 2015; Lacroix & Saussereau, 2012; Nguyen et al., 2018). 50 µl of plasma were mixed with 50 µl of deuterated internal standard (100 ng/ml CBD-d3 and THC-d3; Cerilliant), and cannabinoids were extracted into 300 µL acetonitrile and 600 µl of chloroform and then dried. Samples were reconstituted in 100 µl of an acetonitrile/methanol/water (2:1:1). Separation was performed on an Agilent LC1100 using an Eclipse XDB-C18 column (3.5µm, 2.1mm × 100mm) using gradient elution with water and methanol, both with 0.2 % formic acid (300 µl/min; 73–90%). Cannabinoids were quantified using an Agilent MSD6140 single quadrodpole using electrospray ionization and selected ion monitoring [CBD (m/z=315.2), CBD-d3 (m/z=318.2), THC (m/z=315.2) and THC-d3 (m/z=318.2)]. Calibration curves were conducted daily for each assay at a concentration range of 0–200 ng/mL and observed correlation coefficients were 0.999.

## 2.7. Experiments

The experimental treatments of groups are described below, additional details on the groups can be found in the Supplemental Methods.

**2.7.1. Experiment 1 (Nociception in male and female Wistar rats)**—Tail-withdrawal latency was assessed in male (N=8) and female (N=7) Wistar rats 35, 60 and 120 minutes after initiation of vapor inhalation of PG or THC (100 mg/mL for 30 minutes with 4 puffs every 5 minutes) with SR141716 (0, 4 mg/kg SR, i.p.) administered 15 minutes prior to PG or THC. Treatment order of these three conditions was counter-balanced within both male and female groups, with the vapor inhalations conditions conducted in same-sex pairs.

**2.7.2. Experiment 2 (SR141716 in male Sprague-Dawley and Wistar rats)**—A group (N=8) of male Sprague-Dawley rats received either the vehicle or SR141716 (4 mg/kg, i.p.) 15 minutes before the initiation of THC (200 mg/mL) inhalation for 20 minutes. This group next participated in a series of studies in which they were exposed to PG or THC (200 mg/mL) vapor for 20 or 30 minutes following injection of either the vehicle or SR141716 (4 mg/kg, i.p.). The pre-treatment interval was 90 minutes before the initiation of inhalation. These eight conditions were counter-balanced across the group with THC administered no more frequently than once per week. The group next participated in a study in which they were exposed to THC (200 mg/mL) vapor for 30 minutes and injected with either the vehicle or SR141716 (4 mg/kg, i.p.) after the inhalation session and prior to the start of telemetry recording. For the final study in this experiment, a group (N=13) of male Wistar rats received injection of either the vehicle or SR141716 (10 mg/kg, i.p.) 20 minutes before the initiation of THC (200 mg/mL) inhalation for 20 minutes.

**2.7.3. Experiment 3 (SR141716 after THC, i.p., in male Sprague-Dawley rats)**—A study of the effect of SR141716 (4 mg/kg, i.p.), or vehicle, injected 90 minutes after THC (20 mg/kg, i.p.), or vehicle, was conducted in a second group of male Sprague-Dawley rats.

**2.7.4. Experiment 4 (THC, i.v., in male and female Wistar rats)**—Groups of male (N=8) and female (N=5) Wistar rats were injected with THC (0.0, 0.1, 0.3 and 1.0, i.v.) in a counterbalanced order prior to telemetry recording of temperature and activity. Following these studies, the groups completed a study in which they received THC (0.0, 1.0 mg/kg, i.v.) with SR141716 (0.0, 4.0 mg/kg, i.p.) injected 15 minutes prior, for four total treatment conditions in a counterbalanced order.

**2.7.5. Experiment 5 (Antagonist Challenge After Repeated THC Vapor Inhalation in female Wistar rats)**—In the first week, a group (N=8) of female rats received four days of twice-daily, 30-minute inhalation sessions of vapor from the PG vehicle (5.25 h interval between session initiations on each day). The following week, rats received five days of twice daily, 30-minute inhalation of THC (100 mg/mL) vapor, again with 5.25 h between sessions. The antagonist study was conducted starting 20 days after the final post-chronic THC-inhalation assessment, using pretreatment with 4 mg/kg, i.p. of the CB<sub>1</sub> antagonists/inverse agonists SR141716 and AM-251 and the CB<sub>2</sub> antagonist/inverse agonist AM-630. In these studies, the THC exposures were no more frequent than a 7 day interval and the order of the pre-treatment / inhalation conditions was counter-balanced across the group within each antagonist study. The final study was conducted in the same group, to determine the effect of SR141716 (4 mg/kg, i.p.) and AM-251 (4 mg/kg, i.p.) on



the hypothermic effect of injected THC (10 mg/kg, i.p.). For these studies, the vehicle or one of the two antagonists were administered 15 minutes prior to injection with THC or Vehicle, with treatment conditions evaluated in a counterbalanced order.

**2.7.6. Experiment 6 (Plasma THC by sex and strain of rat)**—Male and female Wistar and Sprague-Dawley rats (N=6 per group) were prepared with intravenous catheters and permitted to recover for at least a week. Blood samples (~300–500 µl) were obtained through the catheters 35, 60, 120, and 240 minutes after the start of inhalation of THC (100 mg/mL) for 30 minutes. In the next experiment, conducted 5 weeks later, blood samples were obtained at the same time points following injection of THC (10 mg/kg, i.p.); catheters remained patent in only 3 female rats of each strain in the i.p. study thus the female data are not reported. Rats were injected with ~300–500 µl of saline, i.v., after each blood sample was obtained to maintain circulating volume. An experiment involving blood sampling on a similar schedule after a 30 minute session of nicotine (30 mg/mL) vapor inhalation was interposed between these two THC experiments. Blood sampling experiments were conducted no more frequently than every other week to accord with recommendations for blood volume recovery (Diehl et al., 2001).

## 2.8. Data Analysis

The telemeterized body temperature and activity rate (counts per minute) were collected on a 5-minute schedule in telemetry studies but are expressed as 30 minute averages for analysis. The time courses for data collection are expressed relative to the THC injection time or the initiation of vapor inhalation and times in the figures refer to the end of the interval (e.g. “60 minutes” reflects the data collected from 35 to 60 minutes, inclusive). Any missing temperature values were interpolated from the values before and after the lost time point. Activity rate values were not interpolated because 5-minute to 5-minute values can change dramatically, thus there is no justification for interpolating. Group sizes were determined initially with a power analysis of similar data collected previously in the laboratory. Data (tail-withdrawal latency, telemeterized temperature and activity measures, plasma THC concentrations) were generally analyzed with two-way Analysis of Variance (ANOVA) including repeated measures factors for the Drug treatment condition and the Time after vapor initiation or injection with sphericity assumed. A mixed-effects model was used instead of ANOVA wherever there were missing datapoints. Any significant main effects were followed with post-hoc analysis using Tukey (multi-level factors) or Sidak (two-level factors) procedures. All analysis used Prism 8 for Windows (v. 8.4.2; GraphPad Software, Inc, San Diego CA).

## 3. Results

### 3.1. Experiment 1 (Nociception in male and female Wistar rats)

This experiment confirmed that the CB1 antagonist SR141716 partially (female rats) or completely (male rats) blocked the antinociceptive effect of THC inhalation. The analysis of the female rat data (Figure 1) confirmed a significant effect of Drug treatment condition [ $F(2, 12) = 23.01; P < 0.0001$ ] but not of Time after vapor initiation or of the interaction of factors.



Post-hoc analysis of the marginal means confirmed that tail-withdrawal latency differed significantly across all three treatment conditions. The analysis of the male rat data confirmed a significant effect of Drug treatment condition [ $F(2, 14) = 13.54$ ;  $P=0.0005$ ], of Time after vapor initiation [ $F(2, 14) = 5.85$ ;  $P=0.0142$ ] but not of the interaction of factors. The Tukey post-hoc analysis confirmed that tail-withdrawal latency was significantly longer after the Veh-THC condition compared with the SR-PG (35–60 minutes after initiation of inhalation) and SR-THC (35 minutes post-initiation) conditions.

### 3.2. Experiment 2 (SR141716 in male Sprague-Dawley and Wistar rats)

Treatment of male Sprague-Dawley rats ( $N=8$ ) with 4 mg/kg SR141716, i.p., 15 minutes prior to THC (200 mg/L) inhalation for 20 minutes slightly altered the course of the hypothermic response (Figure 2A); the data represented as collected in 5-minute intervals are depicted in Supplemental Figure S1A. The ANOVA confirmed significant effects of Time post-initiation [ $F(6, 42) = 29.65$ ;  $P<0.0001$ ] and of the interaction of Time post-initiation with the pre-treatment condition [ $F(6, 42) = 3.57$ ;  $P<0.01$ ]. The Tukey post-hoc test confirmed that temperature was significantly lower than both pre- inhalation time points for Veh + THC (30–90 minutes after vapor initiation) and for SR141716 + THC (30–60 minutes after vapor initiation). The post-hoc test further confirmed that body temperature was higher 120 minutes after vapor initiation when SR141716 was administered compared with the vehicle.

Increasing the pre-treatment interval so that SR141716 was administered 90 min prior to the initiation of vapor inhalation (THC 200 mg/mL; 20 vs 30 minutes) resulted in a profile of effect (Figure 2B; also see Supplemental Figure S1B) that was similar to that produced by the 15 min pretreatment interval. The three-way ANOVA confirmed significant effects of Inhalation Duration [ $F(1, 168) = 88.42$ ;  $P<0.0001$ ], of Time Post-initiation [ $F(5, 168) = 41.58$ ;  $P<0.0001$ ] and of Vehicle / SR pre-treatment condition [ $F(1, 168) = 9.18$ ;  $P=0.0028$ ]. The 30 minute timepoint for the shorter inhalation condition was omitted in this analysis because it did not exist for the longer inhalation condition. There was also a significant effect of the interaction of Inhalation Duration with Time post-initiation [ $F(5, 168) = 6.14$ ;  $P<0.0001$ ] and the interaction of Inhalation Duration with Vehicle / SR141716 pre-treatment condition [ $F(1, 168) = 4.42$ ;  $P<0.05$ ] on the body temperature. To further explore the interaction, a two-way ANOVA on the 30 minute inhalation conditions confirmed significant effects of Vehicle / SR141716 pre-treatment [ $F(1, 7) = 6.13$ ;  $P=0.0425$ ], Time post-initiation [ $F(5, 35) = 57.20$ ;  $P<0.0001$ ] and the interaction [ $F(5, 35) = 6.56$ ;  $P=0.0002$ ]. The post-hoc test confirmed a significant effect of SR141716 on body temperature from 90–180 minutes after vapor initiation. The temperature data for the PG inhalation conditions and the activity data for the whole study are shown in Supplemental Figure S2.

Administration of SR141716 (4 mg/kg, i.p.) at the end of a 30 minute THC (200 mg/mL) vapor inhalation session likewise modified the course of hypothermia (Figure 2C). The three-factor ANOVA confirmed significant effects of Time after vapor initiation [ $F(4, 140) = 6.37$ ;  $P<0.0001$ ], of Vapor condition [ $F(1, 140) = 197.8$ ;  $P<0.0001$ ], of Vehicle / SR141716 Post-treatment condition [ $F(1, 140) = 4.87$ ;  $P<0.05$ ], of the interaction of Time with Vapor condition [ $F(4, 140) = 11.86$ ;  $P<0.0001$ ], and the interaction of Vapor condition

with Post-treatment condition [ $F(1, 140) = 8.53; P < 0.005$ ] on body temperature. To further parse the effect of SR141716 post-treatment a followup ANOVA was conducted on only the THC-inhalation conditions and the ANOVA confirmed significant effects of Time after vapor initiation [ $F(5, 35) = 41.97; P < 0.0001$ ], and of the interaction of Time with Post-treatment condition [ $F(5, 35) = 5.30; P = 0.001$ ], on body temperature. The posthoc test confirmed that temperature differed between post-treatment condition from 90–150 minutes after the start of inhalation.

Increasing the SR141716 dose to 10 mg/kg, i.p., administered 15 min prior to the start of inhalation (THC 200 mg/mL; 20 minutes) in male Wistar rats (Figure 2D) did not produce a qualitatively different outcome. The analysis confirmed a significant effect of Time Post-initiation [ $F(5, 60) = 61.23; P < 0.0001$ ] and of interaction of Time Post-initiation with Vehicle / SR141716 pre-treatment condition [ $F(5,60) = 6.60; P < 0.0001$ ] on body temperature. The posthoc test confirmed that temperature differed between pre-treatment conditions from 120–150 minutes after the start of inhalation.

### 3.3. Experiment 3 (SR141716 after THC, i.p., in male Sprague-Dawley rats)

This experiment confirmed that a 4 mg/kg, i.p. SR141716 dose was capable of altering the hypothermic response to THC injection when administered 45 minutes (Figure 3A) or 90 minutes (Figure 3B) after the injection, attenuating the response when the body temperature response was first initiated (45 minutes) and reversing it when fully engaged (90 minutes). The ANOVAs confirmed significant effects of Drug Condition, Time post-injection and the interaction on body temperature for the 45 minute [Drug:  $F(1, 7) = 12.57; P < 0.01$ ; Time:  $F(9, 63) = 21.8; P < 0.0001; P < 0.0001$ ; Interaction:  $F(9, 63) = 21.77; P < 0.0001$ ] and 90 minute [Drug:  $F(3, 21) = 45.29; P < 0.0001$ ; Time:  $F(9, 63) = 22.65; P < 0.0001; P < 0.0001$ ; Interaction:  $F(27, 189) = 25.27; P < 0.0001$ ] studies. The SR141716 did not affect activity rate when administered 45 minutes after THC (Figure 3C), as there was no significant effect of Drug condition or interaction with Time post-injection, there was only a main effect of Time [ $F(9, 63) = 16.84; P < 0.0001$ ] on activity rate. In the case of the 90 minute study, the SR reversed the locomotor suppression caused by THC injection (Figure 3D). The ANOVA confirmed significant effects of Drug Condition [ $F(3, 21) = 28.72; P < 0.0001$ ], Time post-injection [ $F(9, 63) = 11.88; P < 0.0001$ ] and the interaction [ $F(27, 189) = 2.43; P = 0.0003$ ] on activity rate. Thus, SR141716 was proved efficacious at *reversing* the effects of THC when injected, using identical methods to record temperature and activity as used in the vapor inhalation study.

### 3.4. Experiment 4 (THC, i.v., in male and female Wistar rats)

The goal was first to determine the timecourse of any thermoregulatory or activity effects, compared with the profile following inhaled or i.p. injected THC which differ significantly in our ongoing studies. A rapid decline of temperature to a nadir is observed within about 60 minutes of initiating vapor inhalation and a recovery within about 3 hours is contrasted with a slow decline to a nadir approximately 5–6 hours after i.p. injection. Temperature was decreased rapidly after i.v. injection in both female (1.0mg/kg, i.v.) and male (0.3, 1.0 mg/kg, i.v.) Wistar rats (Figure 4A,B). One male rat's catheter became non-patent after completing only the vehicle and THC 0.1 mg/kg doses. One female rat's transmitter never

functioned properly. Catheter failure in two of the remaining individuals meant that four female rats contributed to each dose condition and in aggregate it was N=6 for all conditions except N=5 for the 1.0 mg/kg dose condition. The mixed-effects analysis confirmed significant effects of Time [F (8, 48) = 11.07; P<0.0001] and Dose [F (3, 18) = 9.607; P=0.0005] for female rats and of Time [F (8, 56) = 24.54; P<0.0001], Dose [F (3, 21) = 14.65; P<0.0001] and the interaction [F (24, 150) = 3.48; P<0.0001] for the male rats, on body temperature. Activity was reduced in the female group after the 1.0 mg/kg, i.v., dose but the mixed-effects analysis failed to confirm any significant effects of treatment condition on activity in female [Time post-injection: F (8, 48) = 9.06; P<0.0001] or male [Time post-injection: F (8, 56) = 19.91; P<0.0001] groups (Figure 4C,D). The rats had become somewhat tolerant to the effect of 1.0 mg/kg, i.v. by the time of the SR141716 experiment but significant reductions in body temperature were still observed in the vehicle pretreatment, 1.0 mg/kg THC, i.v., condition for both male and female groups (Figure 4E,F). Seven male rats and four female rats had both functional transmitters and catheters for the entire SR141716 study. The ANOVAs confirmed that SR141716 pre-treatment attenuated the effects of THC on body temperature in female [Time: F (8, 24) = 17.88; P<0.0001; Dose Condition: F (3, 9) = 9.32; P<0.005; Interaction: F (24, 72) = 2.99; P<0.0005] and male [Time: F (8, 48) = 19.00; P<0.0001; Dose Condition: F (3, 18) = 3.85; P<0.05] rats. There were no effects of THC on activity rate in either sex (not shown).

### 3.5. Experiment 5 (Antagonist Challenge After Repeated THC Vapor Inhalation in female Wistar rats)

Naïve female rats first exposed to four days of twice-daily inhalation of PG (30 minutes) exhibited no acute reduction in body temperature post-initiation of vapor as is shown in Figure 5A. In contrast body temperature was acutely reduced by inhalation of THC (100 mg/mL; 30 minutes) during the repeated-THC week (Figure 5B). The analysis of variance was conducted on 30-minute bins and included the first session of the day for all nine treatment days. The ANOVA confirmed significant effects of Session [F (8, 56) = 17; P<0.0001], of Time after vapor initiation [F (9, 63) = 19.7; P<0.0001] and of the interaction of factors [F (72, 504) = 9.98; P<0.0001]. The Tukey post-hoc test (see Figure 5 for details) confirmed that there was no reduction in body temperature relative to baseline in the first 180 minutes after the initiation of inhalation for any of the PG sessions. In contrast the inhalation of THC induced a consistent hypothermia relative to the pre-inhalation baseline up to at least 210 minutes after vapor initiation for all five days. Similarly, the post-hoc confirmed that body temperature was lower compared with all four PG sessions 60 minutes after initiation of vapor in all five THC sessions. This continued for up to 180 minutes after initiation on the first two THC sessions. THC-associated hypothermia was significantly attenuated in initial magnitude on THC days 4 and 5 compared with the first three THC days. There were two additional THC sessions conducted 1 and 2 weeks after the repeated THC week (see Supplemental Figure S3).

Additional studies were conducted to probe the dependence of the THC-induced hypothermia on the CB<sub>1</sub> or CB<sub>2</sub> endocannabinoid receptor subtypes, starting 20 days after the prior THC session. For all these experiments the rats were exposed to THC no more frequently than a 7 day interval. In the first experiment (Figure 5C), SR141716 (4 mg/kg,

i.p.) or the vehicle was administered 15 minutes prior to the start of vapor inhalation of PG or 100 mg/mL THC for 30 minutes. The four conditions were conducted in randomized order and the ANOVA confirmed a significant effect of Time after vapor initiation [ $F(8, 56) = 7.38; P < 0.0001$ ], of Treatment condition [ $F(3, 21) = 8.44; P < 0.001$ ] and of the interaction [ $F(24, 168) = 8.08; P < 0.0001$ ]. The Tukey post-hoc test confirmed a significant difference between Vehicle and SR141716 pretreatment conditions from 90–150 minutes after THC vapor initiation and 60 minutes after PG vapor initiation.

In the next experiment either AM-251 (4 mg/kg, i.p.) or the vehicle was administered 15 minutes prior to start of vapor inhalation of 100 mg/mL THC for 30 minutes (Figure 5D). The two conditions were conducted in randomized order. The ANOVA confirmed a significant effect of Time after vapor initiation [ $F(8, 56) = 11.65; P < 0.0001$ ], of Treatment condition [ $F(1, 7) = 18.73; P < 0.005$ ] and of the interaction of factors [ $F(8, 56) = 6.38; P < 0.0001$ ]. The Tukey post-hoc test confirmed a significant difference between Vehicle and AM-251 pre-treatment for 60–180 minutes after the start of vapor. The 5-minute bin analysis shown in Supplemental Figure S1C further emphasizes the initial response under AM251 and SR141716 pre-treatment conditions. Finally, AM-630 (4 mg/kg, i.p.) or the vehicle was administered 15 minutes prior to start of vapor inhalation of PG or 100 mg/mL THC for 30 minutes (Figure 5E). The four conditions were conducted in randomized order and the ANOVA confirmed a significant effect of Time after vapor initiation [ $F(8, 56) = 4.59; P < 0.0005$ ], of Treatment condition [ $F(3, 21) = 23.62; P < 0.0001$ ] and of the interaction [ $F(24, 168) = 4.24; P < 0.0001$ ]. The Tukey post-hoc test confirmed that body temperature was significantly lower compared with both the baseline and the respective PG inhalation condition for Veh-THC (30–180 minutes after initiation of vapor) and for AM-630-THC (30–120 minutes). Body temperature was significantly lower after THC inhalation compared the respective PG conditions up to 240 minutes after the start of inhalation.

For this study the female rats were injected with THC (0, 10 mg/kg i.p.) with the vehicle, SR141716 (4 mg/kg, i.p.) or AM-251 (4 mg/kg, i.p.) administered 15 minutes beforehand. The analysis of all six treatment conditions confirmed a significant effect of Time post-injection [ $F(9, 63) = 22.18; P < 0.0001$ ], of Drug treatment condition [ $F(5, 35) = 4.15; P < 0.005$ ] and of the interaction [ $F(45, 315) = 3.37; P < 0.0001$ ] on body temperature (Figure 6). The Tukey post-hoc test confirmed that temperature was lower than baseline and the respective time points after vehicle-vehicle injection when THC was preceded by the vehicle (30–270 minutes post-injection), when THC was preceded by AM-251 (60–270 minutes post-injection) and when the vehicle was preceded by AM-251 (90–120 minutes post-injection). Temperature was lower in the Veh-THC condition compared with the SR-THC treatment from 30–270 minutes after the THC injection. No significant differences in temperature were confirmed for the SRVeh/SR-THC or AM-251-Veh/AM-251-THC pairs of conditions.

### 3.6. Experiment 6 (Plasma THC by sex and strain of rat)

The thermoregulatory studies presented cross rat age, strain, sex and prior treatment demonstrating how well the effects of CB1 antagonism generalize. Although we've shown previously that male and female Wistar rats achieve similar plasma levels of THC under

identical inhalation conditions (Javadi-Paydar et al., 2018), as do male Wistar and Sprague-Dawley rats across ~1 year of age (Taffe et al., 2020), this sex by strain comparison is necessarily indirect. The present experiment addressed that by treating age matched male and female rats of Wistar and Sprague-Dawley strains with the same inhalation conditions.

The plasma THC concentrations were analyzed first by Group and by Time after vapor initiation (Figure 7). The mixed-effects analysis confirmed a significant effect of Time [F (3, 51) = 55.13, P<0.0001], and of the interaction of Group with Time [F (9, 51) = 2.51, P<0.05]. The post-hoc test of the marginal means confirmed that plasma differed between all time points, save that plasma at 120 minutes did not differ from the levels at either 60 or 240 minutes after vapor initiation. The only Group differences confirmed at a specific time were between female WI and each male Group, 35 minutes after vapor initiation. To further explore the interaction, the data were analyzed first collapsed across strain and then collapsed across sex. The mixed-effects analyses confirmed a significant effect of Time [F (3, 57) = 54.86; P<0.0001] and the interaction of Sex with Time [F (3, 57) = 5.21; P<0.005] on plasma THC concentration when Strain was ignored and of Time [F (3, 57) = 45.86; P<0.0001], but not of Strain or of the interaction, when Sex was ignored. Again, the post-hoc test confirmed the sex difference only at the 35 minute time point.

Insufficient numbers of catheters for the female rats in each group remained patent through the injection study, thus the comparison of i.p. data with the inhalation data focuses only on the male rats (Figure 8). The initial mixed-effects analyses confirmed a significant effect of Time after Initiation or Injection on plasma THC levels within the Sprague-Dawley [F (3, 30) = 23.89, P<0.001] and Wistar groups [F (3, 27) = 37.99, P<0.001]. No significant effects of Route of administration or of the interaction of Route with Time were confirmed within either group. A followup analysis was conducted with the males of both strains included in a single group (Figure 8C). The mixed-effects analysis again confirmed a significant effect of Time after Initiation or Injection [F (3, 33) = 58.45, P<0.001], but not of Route or the interaction of factors, on plasma THC.

#### 4. Discussion

The present study reports a curious inability of the CB<sub>1</sub> inverse agonist/antagonists SR141716 or AM-251 to prevent the hypothermia caused by <sup>9</sup>-tetrahydrocannabinol (THC) when delivered by the inhalation route using an e-cigarette vapor system. The antagonists are active at the doses administered, i.e., against the thermoregulatory effects of parenteral injection of THC, and SR141716 attenuated the antinociceptive effects of vapor inhalation of THC. Nevertheless, the impact of SR141716 pretreatment on *hypothermia* consequent to THC inhalation is limited to moderately accelerating the return of body temperature to the normal range. We have shown in multiple investigations that the inhalation of vapor produced by dissolving THC in the propylene glycol (PG) vehicle of an e-cigarette device, reduces the body temperature of rats and increases tail-withdrawal latency in a nociception assay (Javadi-Paydar, Mehrak et al., 2019; Javadi-Paydar et al., 2018; Nguyen et al., 2016; Nguyen et al., 2020; Nguyen et al., 2018; Taffe et al., 2020). Therefore, this route of administration produces results in rats that are qualitatively similar to effects of THC reported previously in laboratory rodents following parenteral injection (Taffe et al.,

2015; Wiley and Burston, 2014; Wiley et al., 2007) and inhalation using different methods (Lichtman et al., 2001; Marshall et al., 2014). Hypothermic effects are observed in male and female Wistar rats and male Sprague-Dawley rats, but are not observed when the rats inhale vapor produced by the PG vehicle alone. Effects on body temperature are also observed in both adolescent and adult rats of both sexes and repeated (2–3 × daily) exposure induces a partial tolerance (Nguyen et al., 2020; Nguyen et al., 2018). Any differences are mostly in the time-course of effects, which is probably attributable to the depot effects of an i.p. injection relative to other routes such as i.v. injection (Figure 4) or inhalation. Thus, the present result for the body temperature response identify a case in which effects of THC do not differ qualitatively but the lack of dependence of the initial response on CB<sub>1</sub> receptor activation appears to be unique to this route of administration.

Positive control experiments within this set of studies confirm that SR141716 and AM-251 (See Figures 3 and Figure 6) do produce blockade and reversal of the hypothermia produced by i.p. injection of THC in our model, as has been previously reported for SR141716 (Nguyen et al., 2016; Taffe et al., 2015), and that produced by i.v. injection as reported herein (Figure 4). Numerous prior studies of the hypothermia produced by THC when administered by i.p. injection also show that the body temperature effects can be blocked with pre-treatment of the animals with CB<sub>1</sub> receptor inverse agonist/antagonists, such as SR141716 or AM-251 (Nava et al., 2000; Nguyen et al., 2016; Schindler et al., 2017; Taffe et al., 2020). An identical result was found in male rats injected with THC, i.p., in our prior report (Nguyen et al., 2016). In the present studies, we show further that SR141716 arrests the onset of hypothermia when administered 45 min after i.p. injection, and reverses a substantially developed hypothermia when administered 90 after i.p. injection, of THC. The pharmacokinetic study confirmed that minimal differences in plasma THC are found across these vapor conditions and the same i.p. injection dose at these relevant timepoints (Figure 8). Furthermore, the SR141716 dose of 4 mg/kg was sufficient to prevent the hypothermia caused by THC in male and female rats when administered 15 min prior to THC, i.v., and increasing the SR141716 dose to 10 mg/kg in male Wistar rats did not qualitatively alter the failure to arrest the initial hypothermia. Thus it is unlikely that SR141716 is ineffectual to oppose the effects of inhaled THC because of a significant difference in overall, systemic THC dose. Interestingly a prior study of the effects of cannabis smoke inhalation in ICR mice reported no hypothermic effects compared with the placebo smoke condition (Lichtman et al., 2001) which contrasted with a finding in Swiss Webster mice using a THC-infused paper combustion approach (Marshall et al., 2014). As yet unknown strain differences may be critical to the different outcomes in mice, or it could be that subtle methodological differences affect nociception and temperature differently.

This study also confirmed that repeated, twice daily inhalation of THC (100 mg/mL) vapor induces tolerance to hypothermia in adult female rats. Significant tolerance was observed only following the 7<sup>th</sup> session of a twice daily regimen in adult female rats, consistent with our prior report in which rectal temperature was sampled only after the 1<sup>st</sup> and 7<sup>th</sup> sessions (Nguyen et al., 2018) and with our report of a similar timecourse of tolerance development in *adolescent* female rats (Nguyen et al., 2020). We have previously shown that no substantial thermoregulatory tolerance is observed when THC inhalation sessions are spaced by at least 7 days (Javadi-Paydar et al., 2017; Nguyen et al., 2016) and this was confirmed



more directly here since the repeated-exposure animals developed no additional tolerance to intermittent THC challenges (see Supplemental Figure S3). Despite this tolerance, presumably resulting at least in part from a down regulation of CB<sub>1</sub> mediated signaling, the SR141716 pre-treatment produced a similar result as in the other groups, i.e. no alteration in the initial temperature decrement but an accelerated normalization, post-inhalation. There was a partial attenuation of the initial hypothermia produced by inhaled THC followed by an accelerated return to normative temperature when AM-251 was administered, this can be seen most clearly in Supplemental Figure 1C. This difference may be associated with greater efficacy of AM-251. The apparently even more-rapid normalization of temperature associated with the antagonists may be a sex difference but is more likely related to the chronic dosing. This more-rapid return of temperature can be observed in Figure 5B, as well as in our prior report (Nguyen et al., 2020). This experiment has additional translational appeal since human laboratory studies of cannabinoid effects are often conducted with cannabis-experienced individuals who are likely somewhat tolerant to the effects of THC. There was no effect of the CB<sub>2</sub> receptor antagonist/inverse agonist compound AM-630 on the hypothermic response to inhaled THC, confirming the expected selectivity for the CB<sub>1</sub> receptor over the CB<sub>2</sub> receptor. A complete blockade of the effect of i.p. injected THC was, however, produced by SR141716 or AM-251 (Figure 5), although interpretation of the effects of AM-251 are somewhat complex because it lowered the body temperature of female rats by itself. Relatedly, a delay in the ability of SR141716 to counter the effects of injected THC, perhaps due to a decrease associated with the SR141716 itself, have occasionally been reported (Fernandez-Ruiz et al., 1997; Taffe et al., 2015).

It is uncertain at present why the two CB<sub>1</sub> antagonist/inverse agonist compounds did not block the initial hypothermia following inhalation. When administered in these doses, the hypothermia caused by 10 mg/kg THC, i.p., was completely blocked by SR141716 or AM-251 as would be predicted from precedent literature. The nadir of the body temperature observed after inhalation was similar to the nadir reached after i.p. injection, which also suggests a similar effective THC dose in the central nervous system, consistent with the results of the pharmacokinetic study. Importantly, the effects of SR141716 on THC vapor induced antinociception were consistent for 90 minutes, starting from immediately post-session. This difference with the thermoregulatory response may suggest differences in THC penetration of hypothalamic regions over spinal-medullary circuitry (Advokat and Burton, 1987; Fields et al., 1983; Fitton and Pertwee, 1982), but it further emphasizes that simple pharmacokinetics do not explain the curious outcome for hypothermia.

Critically, this phenomenon extended in the present study from male Sprague-Dawley and Wistar rats which had not been exposed to repeated-inhalation conditions on sequential days to a generalization and replication of the effect in the female Wistar rats made tolerant by a prior interval of repeated twice-daily THC inhalation. The difference in SR141716 or AM-251 effect across routes of THC administration may be due to the rapidity with which THC enters the brain during inhalation compared with the antagonist brain entry after injection, however this would require further investigation to confirm. The fact that SR141716 blocked any further temperature reduction when administered 45 min after THC, i.p. and almost immediately reversed hypothermia when administered 90 minutes after THC, i.p., argues against an interpretation based on pharmacological competition, however.



There is little doubt that the hypothermia associated with THC inhalation in this model is caused by pharmacological effects of THC. There is never any effect of the PG vehicle inhalation condition on body temperature, ruling out possible hypoxic effects or pharmacological actions of the PG vapor vehicle. The observed *in vivo* effects are related to THC concentration in the vehicle as well as the duration of exposure at a fixed concentration (Javadi-Paydar et al., 2018; Nguyen et al., 2016; Taffe et al., 2020). It is probable, therefore, that the hypothermia induced by the inhalation of THC is not primarily *initiated* by CB<sub>1</sub> receptor activity. The CB<sub>1</sub> receptor does appear to be involved in the *maintenance* of the response in the ~90 minutes after the nadir is reached and temperature recovery begins to occur. It remains unclear what pharmacological mechanisms might underlie the initiation of hypothermia. Additional studies have shown no ability of the 5-HT<sub>1a</sub> antagonist WAY 100,635 to block hypothermia induced by THC vapor in male Wistar rats (Javadi-Paydar, M. et al., 2019) and that the nociceptin/orphanin FQ peptide (NOP) receptor antagonist JTC-801 (1 mg/kg, i.p.) has no effect on hypothermia induced by 20 min inhalation of THC (200 mg/mL) in male Wistar rats (not shown) as predicted by (Rawls et al., 2007). It remains possible that multiple systems are involved in an approximately substitutable manner and that poly-antagonist pharmacology would be required to resolve the mechanism satisfactorily.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgements:

This work was supported by USPHS grants R01 DA024105 (Taffe, PI), R44 DA041967 (Cole, PI) and R01 DA035482 (Taffe, PI). The National Institutes of Health / NIDA had no direct influence on the design, conduct, analysis or decision to publication of the findings. La Jolla Alcohol Research, Inc. provided funding through a subcontract of R44 DA041967 and donated some necessary equipment and technical support. LJARI did not influence the study designs, the data analysis or the decision to publish findings. Portions of these data were reported in pre-print form in Nguyen et al 2017 (version 1) <https://www.biorxiv.org/content/10.1101/172759v1.full> (Nguyen et al., 2017).

### Abbreviations:

<b>PG</b>	propylene glycol
<b>SR141716 (SR)</b>	5-(4-Chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl- <i>N</i> -(piperidin-1-yl)-1 <i>H</i> -pyrazole-3-carboxamide
<b>AM-251</b>	<i>N</i> -(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1 <i>H</i> -pyrazole-3-carboxamide
<b>AM-630</b>	6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1 <i>H</i> -indol-3-yl](4-methoxyphenyl)methanone
<b>THC <sup>9</sup></b>	tetrahydrocannabinol

## References:

- Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA, 2013 The novel recreational drug 3,4-methylenedioxypropylvalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. *Neuropharmacology* 71, 130–140. [PubMed: 23597511]
- Abel EL, 1973 Chronopharmacology of delta9-tetrahydrocannabinol hypothermia in mice. *Experientia* 29(12), 1528–1529. [PubMed: 4772055]
- Advokat C, Burton P, 1987 Antinociceptive effect of systemic and intrathecal morphine in spinally transected rats. *Eur J Pharmacol* 139(3), 335–343. [PubMed: 3666009]
- Borgen LA, Lott GC, Davis WM, 1973 Cannabis-induced hypothermia: a dose-effect comparison of crude marijuana extract and synthetic 9-tetrahydrocannabinol in male and female rats. *Res Commun Chem Pathol Pharmacol* 5(3), 621–626. [PubMed: 4701259]
- Bruijnzeel AW, Qi X, Guzhva LV, Wall S, Deng JV, Gold MS, Febo M, Setlow B, 2016 Behavioral Characterization of the Effects of Cannabis Smoke and Anandamide in Rats. *PLoS one* 11(4), e0153327. [PubMed: 27065006]
- Clark WG, Clark YL, 1981 Changes in body temperature after administration of antipyretics, LSD, delta 9-THC, CNS depressants and stimulants, hormones, inorganic ions, gases, 2,4-DNP and miscellaneous agents. *Neurosci Biobehav Rev* 5(1), 1–136. [PubMed: 6112723]
- Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, Vidal JM, van de Vorstenbosch C, 2001 A good practice guide to the administration of substances and removal of blood, including routes and volumes. *J Appl Toxicol* 21(1), 15–23. [PubMed: 11180276]
- Fernandez-Ruiz JJ, Munoz RM, Romero J, Villanua MA, Makriyannis A, Ramos JA, 1997 Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. *Biochemical pharmacology* 53(12), 1919–1927. [PubMed: 9256167]
- Fields HL, Bry J, Hentall I, Zorman G, 1983 The activity of neurons in the rostral medulla of the rat during withdrawal from noxious heat. *J Neurosci* 3(12), 2545–2552. [PubMed: 6317812]
- Fitton AG, Pertwee RG, 1982 Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-tetrahydrocannabinol. *Br J Pharmacol* 75(2), 409–414. [PubMed: 6313110]
- Freels TG, Baxter-Potter LN, Lugo JM, Glodosky NC, Wright HR, Baglot SL, Petrie GN, Yu Z, Clowers BH, Cuttler C, Fuchs RA, Hill MN, McLaughlin RJ, 2020 Vaporized Cannabis Extracts Have Reinforcing Properties and Support Conditioned Drug-Seeking Behavior in Rats. *J Neurosci* 40(9), 1897–1908. [PubMed: 31953372]
- Grim TW, Morales AJ, Thomas BF, Wiley JL, Endres GW, Negus SS, Lichtman AH, 2017 Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model. *J Pharmacol Exp Ther* 362(1), 210–218. [PubMed: 28442584]
- Hardman HF, Domino EF, Seevers MH, 1971 General pharmacological actions of some synthetic tetrahydrocannabinol derivatives. *Pharmacol Rev* 23(4), 295–315. [PubMed: 5002533]
- Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R, 2006 Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. *J Pharm Sci* 95(6), 1308–1317. [PubMed: 16637053]
- Javadi-Paydar M, Creehan KM, Kerr TM, Taffe MA, 2019 Vapor inhalation of cannabidiol (CBD) in rats. *Pharmacol Biochem Behav* 184, 172741. [PubMed: 31336109]
- Javadi-Paydar M, Kerr TM, Harvey EL, Cole M, Taffe MA, 2019 Effects of Nicotine and THC Vapor Inhalation Administered by An Electronic Nicotine Delivery System (ENDS) in Male Rats. *bioRxiv*, 418699.
- Javadi-Paydar M, Nguyen JD, Grant Y, Vandewater SA, Cole M, Taffe MA, 2017 Effects Of 9-THC And Cannabidiol Vapor Inhalation In Male And Female Rats. *bioRxiv* doi: 10.1101/128173.
- Javadi-Paydar M, Nguyen JD, Kerr TM, Grant Y, Vandewater SA, Cole M, Taffe MA, 2018 Effects of Delta9-THC and cannabidiol vapor inhalation in male and female rats. *Psychopharmacology (Berl)* 235(9), 2541–2557. [PubMed: 29907926]


- Lefever TW, Marusich JA, Thomas BF, Barrus DG, Peiper NC, Kevin RC, Wiley JL, 2017 Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. *Subst Abuse* 11, 1178221817701739.
- Lichtman AH, Martin BR, 1990 Spinal action of cannabinoid-induced antinociception. *NIDA Res Monogr* 105, 422–424. [PubMed: 1876060]
- Lichtman AH, Peart J, Poklis JL, Bridgen DT, Razdan RK, Wilson DM, Poklis A, Meng Y, Byron PR, Martin BR, 2000 Pharmacological evaluation of aerosolized cannabinoids in mice. *Eur J Pharmacol* 399(2–3), 141–149. [PubMed: 10884513]
- Lichtman AH, Poklis JL, Poklis A, Wilson DM, Martin BR, 2001 The pharmacological activity of inhalation exposure to marijuana smoke in mice. *Drug Alcohol Depend* 63(2), 107–116. [PubMed: 11376914]
- Marshall R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, Fantegrossi WE, 2014 In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Delta-THC in mice: Inhalation versus intraperitoneal injection. *Pharmacol Biochem Behav* 124C, 40–47.
- McMahon LR, Amin MR, France CP, 2005 SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys. *Behav Pharmacol* 16(5–6), 363–372. [PubMed: 16148440]
- McMahon LR, Koek W, 2007 Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. *Eur J Pharmacol* 569(1–2), 70–76. [PubMed: 17553486]
- Miller ML, Creehan KM, Angrish D, Barlow DJ, Houseknecht KL, Dickerson TJ, Taffe MA, 2013 Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). *Drug Alcohol Depend* 127(1–3), 248–253. [PubMed: 22832282]
- Morean ME, Kong G, Camenga DR, Cavallo DA, Krishnan-Sarin S, 2015 High School Students' Use of Electronic Cigarettes to Vaporize Cannabis. *Pediatrics* 136(4), 611–616. [PubMed: 26347431]
- Morean ME, Lipshie N, Josephson M, Foster D, 2017 Predictors of Adult E-Cigarette Users Vaporizing Cannabis Using E-Cigarettes and Vape-Pens. *Subst Use Misuse* 52(8), 974–981. [PubMed: 28323498]
- Nava F, Carta G, Battasi AM, Gessa GL, 2000 D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. *Br J Pharmacol* 130(6), 1201–1210. [PubMed: 10903956]
- Nguyen JD, Aarde SM, Vandewater SA, Grant Y, Stouffer DG, Parsons LH, Cole M, Taffe MA, 2016 Inhaled delivery of Delta(9)-tetrahydrocannabinol (THC) to rats by e-cigarette vapor technology. *Neuropharmacology* 109, 112–120. [PubMed: 27256501]
- Nguyen JD, Creehan KM, Grant Y, Vandewater SA, Cole M, Taffe MA, 2017 Repeated Vapor Inhalation of 9-tetrahydrocannabinol Induces Tolerance to Hypothermia In Female Rats. *BioRxiv* 08/04/2017.
- Nguyen JD, Creehan KM, Kerr TM, Taffe MA, 2020 Lasting effects of repeated (9)-tetrahydrocannabinol vapour inhalation during adolescence in male and female rats. *Br J Pharmacol* 177(1), 188–203. [PubMed: 31478558]
- Nguyen JD, Grant Y, Kerr TM, Gutierrez A, Cole M, Taffe MA, 2018 Tolerance to hypothermic and antinociceptive effects of 9-tetrahydrocannabinol (THC) vapor inhalation in rats. *Pharmacol Biochem Behav* 172, 33–38. [PubMed: 30031028]
- Perrine CG, Pickens CM, Boehmer TK, King BA, Jones CM, DeSisto CL, Duca LM, Lekiachvili A, Kenemer B, Shamout M, Landen MG, Lynfield R, Ghinai I, Heinzerling A, Lewis N, Pray IW, Tanz LJ, Patel A, Briss PA, Lung Injury Response Epidemiology/Surveillance, G., 2019 Characteristics of a Multistate Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping - United States, 2019. *MMWR Morb Mortal Wkly Rep* 68(39), 860–864. [PubMed: 31581168]
- Rawls SM, Schroeder JA, Ding Z, Rodriguez T, Zaveri N, 2007 NOP receptor antagonist, JTC-801, blocks cannabinoid-evoked hypothermia in rats. *Neuropeptides* 41(4), 239–247. [PubMed: 17512052]
- Schindler CW, Gramling BR, Justinova Z, Thorndike EB, Baumann MH, 2017 Synthetic cannabinoids found in “spice” products alter body temperature and cardiovascular parameters in conscious male rats. *Drug Alcohol Depend* 179, 387–394. [PubMed: 28846955]

- Schmeling WT, Hosko MJ, 1980 Hypothermic effects of intraventricular and intravenous administration of cannabinoids in intact and brainstem transected cats. *Neuropharmacology* 19(6), 567–573. [PubMed: 7402446]
- Taffe MA, 2012 Delta9-Tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys. *Neuroscience* 201, 125–133. [PubMed: 22138434]
- Taffe MA, Creehan KM, Vandewater SA, 2015 Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Delta(9)-tetrahydrocannabinol in Sprague-Dawley rats. *Br J Pharmacol* 172(7), 1783–1791. [PubMed: 25425111]
- Taffe MA, Creehan KM, Vandewater SA, Kerr TM, Cole M, 2020 Effects of Delta(9)-tetrahydrocannabinol (THC) vapor inhalation in Sprague-Dawley and Wistar rats. *Exp Clin Psychopharmacol*.
- Taylor DA, Fennessy MR, 1977 Biphasic nature of the effects of delta9-tetrahydrocannabinol on body temperature and brain amines of the rat. *Eur J Pharmacol* 46(2), 93–99. [PubMed: 590330]
- Vidal C, Suaudeau C, Jacob J, 1984 Regulation of body temperature and nociception induced by non-noxious stress in rat. *Brain Res* 297(1), 1–10. [PubMed: 6722530]
- Wang XF, Galaj E, Bi GH, Zhang C, He Y, Zhan J, Bauman MH, Gardner EL, Xi ZX, 2020 Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB1 /CB2 versus GPR55 receptors. *Br J Pharmacol* 177(8), 1865–1880. [PubMed: 31877572]
- Wiley JL, Burston JJ, 2014 Sex differences in Delta(9)-tetrahydrocannabinol metabolism and in vivo pharmacology following acute and repeated dosing in adolescent rats. *Neurosci Lett* 576, 51–55. [PubMed: 24909619]
- Wiley JL, Marusich JA, Huffman JW, 2014 Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. *Life Sci* 97(1), 55–63. [PubMed: 24071522]
- Wiley JL, O'Connell MM, Tokarz ME, Wright MJ Jr., 2007 Pharmacological effects of acute and repeated administration of Delta(9)-tetrahydrocannabinol in adolescent and adult rats. *J Pharmacol Exp Ther* 320(3), 1097–1105. [PubMed: 17172531]
- Wilson DM, Peart J, Martin BR, Bridgen DT, Byron PR, Lichtman AH, 2002 Physiochemical and pharmacological characterization of a Delta(9)-THC aerosol generated by a metered dose inhaler. *Drug Alcohol Depend* 67(3), 259–267. [PubMed: 12127197]
- Wright MJ Jr., Angrish D, Aarde SM, Barlow DJ, Buczynski MW, Creehan KM, Vandewater SA, Parsons LH, Houseknecht KL, Dickerson TJ, Taffe MA, 2012 Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. *PloS one* 7(8), e44652. [PubMed: 22952999]
- Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI, 1999 Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. *Proc Natl Acad Sci U S A* 96(10), 5780–5785. [PubMed: 10318961]
- Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JC, Verpoorte R, Pinquier JL, Cohen AF, van Gerven JM, 2008 Effect of intrapulmonary tetrahydrocannabinol administration in humans. *J Psychopharmacol* 22(7), 707–716. [PubMed: 18515447]


### Highlights

Vapor inhalation of THC produces anti-nociception and hypothermia in rats. Anti-nociceptive effects are prevented by the CB1 receptor antagonist SR141716. The antagonist fails to block initial hypothermia caused by THC inhalation.

CB1 receptor may be involved in maintenance but not induction of hypothermia.




**Figure 1:** Mean tail-withdrawal latencies for female (N=7;  $\pm$ SEM) and male (N=8;  $\pm$ SEM) Wistar rats after pre-treatment with SR141716 (SR; 4 mg/kg, i.p.) or the vehicle (Veh) and inhalation of PG or THC (100 mg/mL) vapor. Significant differences between pairs of conditions or the marginal means are indicated with \*.




**Figure 2:** Mean body temperature of male A-C) Sprague-Dawley (N=8;  $\pm$ SEM) and D) Wistar (N=13;  $\pm$ SEM) rats following vapor inhalation of THC (200 mg/mL) for 20 (THC 20) or 30 (THC 30) minutes. The effect of the CB1 antagonist SR141716 (SR; 4 mg/kg, i.p.) was assessed for the Sprague-Dawley rats A) 15 minutes before vapor initiation; B) 90 minutes prior to vapor initiation and C) after vapor cessation. D) The effect of (SR; 10 mg/kg, i.p.; 20 minutes prior to inhalation) on temperature disruption associated with THC (200 mg/mL) inhalation for 20 minutes was assessed for the Wistar rats. Arrows indicate the timing of the vehicle/SR141716 injection. Shaded symbols indicate a significant difference from the baseline value, and a significant difference between SR141716 (SR) pretreatment conditions is indicated with \*. The PG vapor inhalation condition was used in lieu of a baseline measure for confirmation of hypothermia in the post-vapor SR141716 experiment, thus open symbols indicate a significant difference from the respective PG inhalation condition.







**Figure 3:** Mean (N=8; ±SEM) temperature (A, B) and Activity rate (C, D) for male Sprague-Dawley rats injected (i.p.) with THC (20 mg/kg) and then SR141716 (4 mg/kg) or the vehicle (Veh) either 45 (A, C) or 90 (B, D) minutes later. Arrows indicate the timing of the vehicle/ SR141716 injection. The vehicle control for THC was included in the 90 minute study only. Shaded symbols indicate a significant difference from the 30 minute value, within treatment condition. Open symbols indicate a significant difference from the 30 minute value and the respective Vehicle condition; a difference from the Vehicle only is indicated with \*. A significant difference between SR141716 (SR) treatment conditions is indicated with #.




**Figure 4:** Mean ( $\pm$ SEM) temperature (A, B) and Activity (C, D) response to THC injection (i.v.) in female (A, C) and male (B, D) Wistar rats. Group sizes range from N=5–8, see text. Mean ( $\pm$ SEM) temperature response to THC injection (i.v.) in E) female (N=4) and F) male (N=7) rats after injection (i.p.) with SR141716 (SR) or the vehicle (Veh). Shaded symbols indicate a significant difference from the baseline (Base), within treatment condition. Open symbols indicate a significant difference from the baseline and the respective Vehicle (i.v.) condition at a given time after injection. A significant difference from all other treatment conditions at a given time after injection is indicated with \* and a difference from the 0.1 mg/kg condition with #. A significant difference between pre-treatment conditions, within vapor inhalation conditions, is indicated with &.




**Figure 5:** Mean (N=8; ±SEM) body temperature of female Wistar rats before (Base= baseline) and after vapor inhalation of A) PG or B) THC (100 mg/mL) for 30 minutes. Shaded symbols indicate a significant difference from the within-day baseline value, open symbols indicate a significant difference from the baseline and the respective time during **all four** PG inhalation days. A significant difference from PG day 1 is indicated by \*, a difference from THC day 1 by #, a significant difference from THC days 1–3 by %, a significant difference from THC days 1 and 3 by &, and a significant difference between THC 4 and THC 5 by §; a bar indicates all other days differ. Mean (N=8; ±SEM) body temperature of female Wistar rats before (Base= baseline) and after vapor inhalation of PG or THC (100 mg/mL) for 30 minutes. Experiments included pretreatment of animals with CB1 antagonist/inverse agonists C) SR141716 and D) AM-251 as well as E) the CB2 antagonist AM-630. Shaded symbols indicate a significant difference from the baseline value, open symbols indicate a significant difference from the baseline and the respective time in the corresponding PG inhalation condition (when run). A significant difference from the respective PG condition only is indicated with ‡. A significant difference between vehicle and antagonist pretreatment conditions is indicated with @.



**Figure 6.** Mean (N=8;  $\pm$ SEM) body temperature of female Wistar rats after i.p. injection of THC (10 mg/kg) or the Vehicle following pre-treatment with left) SR141716 (4 mg/kg, i.p.) or right) AM-251 (4 mg/kg, i.p.). The Vehicle-Vehicle and Vehicle-THC conditions are depicted in both panels to facilitate comparison. Shaded symbols indicate a significant difference from the baseline value, open symbols indicate a significant difference from the baseline and the Vehicle-Vehicle condition. A significant difference from the Vehicle-Vehicle condition, but not the baseline, is indicated with \* and a difference between Veh and SR141716 pre-treatment THC conditions is indicated with #.



**Figure 7:** Mean ( $\pm$ SEM) plasma THC concentrations after vapor inhalation of THC (100 mg/mL; 30 minutes) in male and female A) Sprague-Dawley and B) Wistar rats. The data are also presented C) collapsed across sex, by strain (All timepoints differ significantly within SD and WI groups, save 60 and 120 minutes within the WI group do not differ from each other); and D) collapsed across strain, by sex (All timepoints differ significantly from each other within male and female groups). In all panels, a significant difference from the 35 minute timepoint is indicated with \* and significant differences between groups with #. The final two timepoints were missing for one WI male and one WI female rat, and the final timepoint was missing for one female SD and one female WI rat in this study.



**Figure 8:** Mean plasma THC concentrations for A) Sprague-Dawley males, B) Wistar males or C) all males after vapor inhalation of THC (100 mg/mL) for 30 minutes or injection with THC (10 mg/kg, i.p.). N=6 per group save that the final timepoint was missing for one WI male in the IP study and the final two timepoints were missing for the same individual in the vapor inhalation study. A significant difference from the 35-minute sample is indicated with \* and a difference from both 35- and 60-minute samples with \$.

**Table 1:**

Summary of the Experiments conducted. WI, Wistar; SD, Sprague-Dawley

Experiments	Sex/Strain	Assessment	THC Route	Antagonists
Experiment 1	Male/Female WI	Nociception	Inhalation	SR141716
Experiment 2	Male WI and SD	Temperature/Activity	Inhalation	SR141716
Experiment 3	Male WI and SD	Temperature/Activity	Intraperitoneal	SR141716
Experiment 4	Male/Female WI	Temperature/Activity	Intravenous	SR141716
Experiment 5	Female WI	Temperature/Activity	Inhalation / Intraperitoneal	SR141716 / AM251 / AM630
Experiment 6	Male/Female WI and SD	Plasma THC concentration	Inhalation / Intraperitoneal	N/A

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript